Vontz Center for Molecular Studies
Office: 2304; Lab: 1214
University of Cincinnati Medical Center
3125 Eden Avenue
Cincinnati, OH 45267-0521
ken [dot] greis [at] uc [dot] edu
Ken Greis earned his PhD in Biochemistry from the University of Kentucky working with Prof. Sam Turco to understand the structure/function relationship of glycoconjugate survival factors produced by protozoan parasites. He subsequently did postdoctoral research to evaluate the role of glycosylation on tegument proteins in human cytomegalovirus infections at Johns Hopkins under the mentorship of Professors Gerald Hart and Wade Gibson. During a second postdoctoral stint with Prof. Hart at the University of Alabama at Birmingham, Dr. Greis began to transition his research interest into the newly emerging field of protein mass spectrometry in collaboration with Prof. Steve Barnes.
For the past 20 years his research has focused on technology development and the application of mass spectrometry to understand biochemical and biomedical systems. From 1996-2006, he built and lead protein characterization, mass spectrometry and proteomics groups at two pharmaceutical companies-Parke-Davis Pharmaceutical Research (now part of Pfizer) and Procter & Gamble Pharmaceuticals. He has developed significant expertise in mass spectrometry technology development and project management while collaborating in a variety of research areas including: signal transduction, angiogenesis, metabolic regulation (obesity and diabetes), anti-microbial, musculoskeletal, inflammation, cardiovascular and cancer.
In July 2006, Dr. Greis joined the University of Cincinnati faculty where he is now an Associate Professor of Cancer Biology and the Director of Proteomics and Mass Spectrometry for the University and Cincinnati Children's Hospital Medical Center. In this role he acts both as the core director and as a primary collaborator with many investigators on grant supported research that requires expertise in biological mass spectrometry. His independent research is focused on global phosphorylation profiling by isotope tagging and quantitative mass spectrometry and the development of a novel mass spectrometry-based high throughput screening platform.